Citadel Advisors’s Ultralife ULBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-1,700
Closed -$9.15K 15202
2025
Q1
$9.15K Buy
+1,700
New +$11.6K ﹤0.01% 13616
2024
Q4
Sell
-100
Closed -$904 15429
2024
Q3
$904 Sell
100
-2,800
-97% -$28.9K ﹤0.01% 13939
2024
Q2
$30.8K Sell
2,900
-9,100
-76% -$96.9K ﹤0.01% 12241
2024
Q1
$106K Buy
12,000
+8,200
+216% +$66.7K ﹤0.01% 11279
2023
Q4
$25.9K Sell
3,800
-1,200
-24% -$9.85K ﹤0.01% 12393
2023
Q3
$48.8K Buy
5,000
+4,000
+400% +$32K ﹤0.01% 11783
2023
Q2
$4.84K Sell
1,000
-15,600
-94% -$67.8K ﹤0.01% 13565
2023
Q1
$66.7K Buy
16,600
+6,100
+58% +$24.5K ﹤0.01% 11798
2022
Q4
$40.5K Buy
+10,500
New +$48.4K ﹤0.01% 12403
2022
Q3
Sell
-13,200
Closed -$60K 13646
2022
Q2
$60K Buy
+13,200
New +$65K ﹤0.01% 11813
2021
Q2
Sell
-11,500
Closed -$95K 14470
2021
Q1
$95K Buy
+11,500
New +$81.5K ﹤0.01% 12510

Other funds holding ULBI

Citadel Advisors's ULBI Position: Q1 2026 in Review

Citadel Advisors reduced its Ultralife (ULBI) stake by 55% in Q1 2026, selling an estimated $316K and leaving 41,301 shares worth $269K. The position accounts for ﹤0.01% of the portfolio, ranked #10713.

Citadel Advisors first reported a position in ULBI in Q1 2014 and has held it in 15 quarters since. The position peaked at $829K in Q3 2024. 50 funds tracked by Wall St. Rank hold ULBI as of Q1 2026.

  • Citadel Advisors held 41,301 shares of Ultralife worth $269K as of Q1 2026.
  • Citadel Advisors sold 50,812 Ultralife shares in Q1 2026, an estimated $316K.
  • Ultralife made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10713 holding.
  • Citadel Advisors first reported a position in Ultralife in Q1 2014 and has held it in 15 quarters since.
  • Citadel Advisors's Ultralife position peaked at $829K in Q3 2024.
  • 50 funds tracked by Wall St. Rank held Ultralife as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.